165 related articles for article (PubMed ID: 37390632)
21. Synthesis and biological evaluation of 7-alkenyl homocamptothecins as potent topoisomerase I inhibitors.
Zhu L; Zhang X; Lei N; Liu W; Miao Z; Zhuang C; Sheng C; Guo W; Dong G; Yao J; Cheng P; Zhang W
Chem Biodivers; 2012 Jun; 9(6):1084-94. PubMed ID: 22700227
[TBL] [Abstract][Full Text] [Related]
22. Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study.
Tesauro C; Simonsen AK; Andersen MB; Petersen KW; Kristoffersen EL; Algreen L; Hansen NY; Andersen AB; Jakobsen AK; Stougaard M; Gromov P; Knudsen BR; Gromova I
BMC Cancer; 2019 Nov; 19(1):1158. PubMed ID: 31783818
[TBL] [Abstract][Full Text] [Related]
23. The design and discovery of topoisomerase I inhibitors as anticancer therapies.
Martín-Encinas E; Selas A; Palacios F; Alonso C
Expert Opin Drug Discov; 2022 Jun; 17(6):581-601. PubMed ID: 35321631
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis and antineoplastic activity of novel 20(S)-acylthiourea derivatives of camptothecin.
Yang CJ; Li B; Zhang ZJ; Gao JM; Wang MJ; Zhao XB; Song ZL; Liu YQ; Li H; Chen Y; Lee KH; Morris-Natschke SL; Xu C
Eur J Med Chem; 2020 Feb; 187():111971. PubMed ID: 31881457
[TBL] [Abstract][Full Text] [Related]
25. Camptothecin (CPT) directly binds to human heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) and inhibits the hnRNP A1/topoisomerase I interaction.
Manita D; Toba Y; Takakusagi Y; Matsumoto Y; Kusayanagi T; Takakusagi K; Tsukuda S; Takada K; Kanai Y; Kamisuki S; Sakaguchi K; Sugawara F
Bioorg Med Chem; 2011 Dec; 19(24):7690-7. PubMed ID: 22071521
[TBL] [Abstract][Full Text] [Related]
26. Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH.
Gabr A; Kuin A; Aalders M; El-Gawly H; Smets LA
Cancer Res; 1997 Nov; 57(21):4811-6. PubMed ID: 9354443
[TBL] [Abstract][Full Text] [Related]
27. TCH-1030 targeting on topoisomerase I induces S-phase arrest, DNA fragmentation, and cell death of breast cancer cells.
Liu YP; Chen HL; Tzeng CC; Lu PJ; Lo CW; Lee YC; Tseng CH; Chen YL; Yang CN
Breast Cancer Res Treat; 2013 Apr; 138(2):383-93. PubMed ID: 23430225
[TBL] [Abstract][Full Text] [Related]
28. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice.
Kim R; Hirabayashi N; Nishiyama M; Jinushi K; Toge T; Okada K
Int J Cancer; 1992 Mar; 50(5):760-6. PubMed ID: 1312063
[TBL] [Abstract][Full Text] [Related]
29. 9-Nitro-20(S)-carbonate-camptothecin (NCP4), a novel prodrug of 9-nitrocamptothecin (9-NC), exhibits potent chemotherapeutic efficacy and improved safety against hepatocarcinoma.
Zhou H; Zhang Y; Tian Y; Sun Y; Chen Y; Zhang Y; Zhu Q; Pan J; Qing C
Eur J Pharmacol; 2022 May; 923():174898. PubMed ID: 35305999
[TBL] [Abstract][Full Text] [Related]
30. An overview of topoisomerase I-targeting agents.
Arbuck SG; Takimoto CH
Semin Hematol; 1998 Jul; 35(3 Suppl 4):3-12. PubMed ID: 9779876
[TBL] [Abstract][Full Text] [Related]
31. Quercetin exerts synergetic anti-cancer activity with 10-hydroxy camptothecin.
Tang Q; Ji F; Wang J; Guo L; Li Y; Bao Y
Eur J Pharm Sci; 2017 Nov; 109():223-232. PubMed ID: 28822757
[TBL] [Abstract][Full Text] [Related]
32. Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors.
Tomicic MT; Kaina B
Biochim Biophys Acta; 2013 Jan; 1835(1):11-27. PubMed ID: 23006513
[TBL] [Abstract][Full Text] [Related]
33. Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines.
Janss AJ; Cnaan A; Zhao H; Shpilsky A; Levow C; Sutton L; Phillips PC
Anticancer Drugs; 1998 Aug; 9(7):641-52. PubMed ID: 9773809
[TBL] [Abstract][Full Text] [Related]
34. SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15.
Tessema M; Yingling CM; Thomas CL; Klinge DM; Bernauer AM; Liu Y; Dacic S; Siegfried JM; Dahlberg SE; Schiller JH; Belinsky SA
Oncogene; 2012 Sep; 31(37):4107-16. PubMed ID: 22158045
[TBL] [Abstract][Full Text] [Related]
35. Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo.
Pollack IF; Erff M; Bom D; Burke TG; Strode JT; Curran DP
Cancer Res; 1999 Oct; 59(19):4898-905. PubMed ID: 10519402
[TBL] [Abstract][Full Text] [Related]
36. Synthesis of 9-(heteroarylmethylidene)amino derivatives of homocamptothecin with biological activities.
Guo W; Miao Z; Sheng C; Yao J; Liu W; Zhu L; Zhang Y; Cheng P; Dong G; Zhuang C; Zhang W
Chem Biodivers; 2011 Jul; 8(7):1266-73. PubMed ID: 21766447
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and biological evaluation of novel homocamptothecins conjugating with dihydropyrimidine derivatives as potent topoisomerase I inhibitors.
Zhu L; Cheng P; Lei N; Yao J; Sheng C; Zhuang C; Guo W; Liu W; Zhang Y; Dong G; Wang S; Miao Z; Zhang W
Arch Pharm (Weinheim); 2011 Nov; 344(11):726-34. PubMed ID: 21956522
[TBL] [Abstract][Full Text] [Related]
38. Gimatecan and other camptothecin derivatives poison Leishmania DNA-topoisomerase IB leading to a strong leishmanicidal effect.
Prada CF; Alvarez-Velilla R; Balaña-Fouce R; Prieto C; Calvo-Álvarez E; Escudero-Martínez JM; Requena JM; Ordóñez C; Desideri A; Pérez-Pertejo Y; Reguera RM
Biochem Pharmacol; 2013 May; 85(10):1433-40. PubMed ID: 23466420
[TBL] [Abstract][Full Text] [Related]
39. CK2-mediated hyperphosphorylation of topoisomerase I targets serine 506, enhances topoisomerase I-DNA binding, and increases cellular camptothecin sensitivity.
Bandyopadhyay K; Li P; Gjerset RA
PLoS One; 2012; 7(11):e50427. PubMed ID: 23185622
[TBL] [Abstract][Full Text] [Related]
40. Topotecan-induced alterations in the amount and stability of human DNA topoisomerase I in solid tumor cell lines.
Devy J; Wargnier R; Pluot M; Nabiev I; Sukhanova A
Anticancer Res; 2004; 24(3a):1745-51. PubMed ID: 15274350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
